Your browser is no longer supported. Please, upgrade your browser.
Settings
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-0.97 Insider Own0.60% Shs Outstand1.10B Perf Week3.93%
Market Cap14.00B Forward P/E4.86 EPS next Y2.62 Insider Trans-2.53% Shs Float1.09B Perf Month22.23%
Income-1059.00M PEG- EPS next Q0.58 Inst Own54.80% Short Float5.26% Perf Quarter21.88%
Sales17.36B P/S0.81 EPS this Y87.00% Inst Trans0.23% Short Ratio3.14 Perf Half Y74.93%
Book/sh12.63 P/B1.01 EPS next Y6.21% ROA-6.80% Target Price11.89 Perf Year-26.38%
Cash/sh1.13 P/C11.28 EPS next 5Y-4.05% ROE-28.00% 52W Range6.07 - 17.90 Perf YTD29.59%
Dividend- P/FCF166.70 EPS past 5Y-28.50% ROI-3.20% 52W High-26.03% Beta2.02
Dividend %- Quick Ratio0.60 Sales past 5Y-1.50% Gross Margin43.40% 52W Low118.12% ATR0.67
Employees42535 Current Ratio0.90 Sales Q/Q-5.90% Oper. Margin-21.00% RSI (14)63.99 Volatility4.85% 5.02%
OptionableYes Debt/Eq1.95 EPS Q/Q-7.20% Profit Margin-23.10% Rel Volume1.41 Prev Close12.70
ShortableYes LT Debt/Eq1.73 EarningsFeb 12 BMO Payout- Avg Volume18.18M Price13.24
Recom2.90 SMA2010.86% SMA5024.38% SMA20046.04% Volume25,599,531 Change4.25%
Feb-24-20Downgrade Edward Jones Hold → Sell
Nov-12-19Upgrade JP Morgan Underweight → Neutral $8
Oct-17-19Upgrade Gabelli & Co Hold → Buy
Aug-07-19Downgrade Evercore ISI Outperform → In-line
Jul-19-19Initiated Wolfe Research Peer Perform
Jul-15-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-10-19Resumed Credit Suisse Neutral
Jul-05-19Upgrade Argus Hold → Buy
Jun-11-19Initiated Barclays Underweight $8
Jun-03-19Upgrade Oppenheimer Perform → Outperform $12
May-30-19Downgrade BofA/Merrill Buy → Underperform
May-28-19Downgrade UBS Buy → Neutral
Mar-20-19Initiated SunTrust Hold
Mar-07-19Resumed UBS Buy $22
Mar-06-19Downgrade Morgan Stanley Overweight → Equal-Weight $17
Feb-20-19Downgrade Mizuho Buy → Neutral $25 → $18
Feb-14-19Upgrade Raymond James Mkt Perform → Outperform $22
Jan-23-19Upgrade UBS Neutral → Buy
Jan-23-19Upgrade Piper Jaffray Underweight → Neutral
Jan-03-19Upgrade BofA/Merrill Underperform → Buy
Feb-25-20 11:24AM  Mallinckrodt Unveils $1.6 Billion Opioid Deal And Generic Stocks Pop Investor's Business Daily
10:14AM  US STOCKS- Wall Street edges higher a day after sharp sell-off Reuters
08:23AM  US STOCKS- Positive earnings boost futures after Monday's selloff Reuters
Feb-24-20 12:41PM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries Zacks
12:25PM  Sanofi Plans Spinoff of Manufacturing Facilities Barrons.com
08:00AM  Teva Announces FDA Approval of ArmonAir® Digihaler (fluticasone propionate) Inhalation Powder Business Wire
Feb-21-20 07:37PM  U.S. FDA approves Lundbeck's migraine prevention therapy Reuters
09:16AM  3 Best Drugmakers That Are Immune to Coronavirus Fright Zacks
Feb-20-20 07:06AM  The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga
Feb-14-20 07:10AM  Positive Earnings Look as If Theyre Already Priced in to Teva Stock InvestorPlace
Feb-13-20 02:42PM  Leaner, More Agile Teva Sees Brighter Days Ahead GuruFocus.com -6.54%
01:31PM  3 Analysts Dissect Teva's Q4 Results Benzinga
08:53AM  Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize Zacks
Feb-12-20 05:19PM  US Indexes Continue Rally Wednesday GuruFocus.com +9.08%
04:50PM  Teva Pharmaceutical CEO on Bringing His Company Back From the Brink Barrons.com
04:14PM  Why Drug Giant Teva Pharma Just Rocketed Into A Profit-Taking Zone Investor's Business Daily
02:16PM  Teva Pharmaceuticals Overtakes Key Level Post-Earnings Schaeffer's Investment Research
09:41AM  Teva Pharmaceutical Jumps After Earnings Meet Wall Street Estimates TheStreet.com
09:05AM  Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up Zacks
08:34AM  Teva Stock Jumps After Reporting Earnings. What You Need to Know. Barrons.com
07:56AM  Teva Reports Q4 Earnings Beat Benzinga
07:35AM  Teva's stock falls on earnings; Copaxone sales tumble 26% MarketWatch
07:30AM  New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion Business Wire
07:09AM  Teva Pharm Q4 profit tops estimates by one cent Reuters
12:55AM  Teva sees higher margins, lower debt from restructuring Financial Times
Feb-11-20 01:13PM  Q4 Earnings Outlook For Teva Benzinga
07:15AM  Teva Reports Earnings Tomorrow. Heres What to Expect. Barrons.com
Feb-10-20 02:43PM  New York Opioid Case A Significant Risk For Pharma Stocks, Says Bearish BofA Benzinga
Feb-07-20 10:28AM  Teva (TEVA) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-05-20 05:50PM  Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know Zacks
Feb-04-20 11:50AM  Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal Zacks +8.16%
10:22AM  Analysts Forecast Huge Upsides for Aimmune, Biohaven GuruFocus.com
Feb-03-20 03:30AM  Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan Business Wire +7.21%
Jan-30-20 10:38AM  Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up Zacks
Jan-29-20 08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
Jan-28-20 04:05PM  Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector Business Wire
02:59AM  Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised) Zacks
Jan-24-20 01:50PM  New partnership aims to ease surging generic drug costs by making its own Yahoo Finance
09:51AM  10 of the Cheapest Warren Buffett Stocks Kiplinger
07:45AM  Investors build war chests to buy bonds of distressed European companies Reuters
Jan-23-20 10:42AM  Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 Zacks
Jan-22-20 10:33AM  J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short Zacks
Jan-21-20 06:21PM  Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks
08:41AM  Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe Zacks
Jan-20-20 08:17AM  J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge Zacks
Jan-15-20 05:00PM  Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance at 8 a.m. ET on February 12, 2020 Business Wire
Jan-14-20 12:59PM  Teva Pharmaceutical Finance Netherlands IV BV -- Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd Moody's +9.49%
Jan-13-20 09:11AM  Endo Up on Opioid Abuse Settlement Agreement With Oklahoma Zacks
Jan-10-20 06:52AM  Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter TheStreet.com
Jan-06-20 05:22PM  Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
02:11PM  Teva agrees to pay $54M to settle whistleblower lawsuit over speaker programs American City Business Journals
01:52PM  New antibiotics struggle to generate sales, pharma companies hurt Yahoo Finance Video
09:00AM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
Jan-03-20 11:49AM  Jeff Clarks Market Minute: These Stocks Will Carry the Market in 2020 InvestorPlace
07:40AM  Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock InvestorPlace
Dec-31-19 09:26AM  Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study Zacks
Dec-30-19 09:12AM  Will J&J be Able to Overcome Its Legal Troubles in 2020? Zacks
06:30AM  Investors Have Been Optimistic About Opioid Litigation. Itll Still Be an Issue in 2020. Barrons.com
Dec-27-19 09:24AM  Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too? Zacks
Dec-24-19 10:12AM  Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy Zacks
Dec-19-19 05:50PM  Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know Zacks
Dec-16-19 07:30AM  NexImmune Appoints Sol Barer as Chairman of the Board of Directors GlobeNewswire
Dec-10-19 10:41AM  Bernard Horn Goes 2 for 2 in 3rd Quarter GuruFocus.com
Dec-09-19 02:30PM  Teva Stock Is Nothing but Trouble after Legal Issues InvestorPlace
Dec-07-19 11:35AM  Did Hedge Funds Drop The Ball On Teva Pharmaceutical Industries Limited (TEVA) ? Insider Monkey
Dec-04-19 05:52PM  Bayer and Teva Double Down on Worst M&A Deals of Decade GuruFocus.com
08:20AM  Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up Zacks
07:59AM  J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders Zacks
Dec-03-19 09:38AM  Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US Zacks
Nov-27-19 12:36PM  Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced MarketWatch +5.88%
09:37AM  Opioid Stocks Fall on News of Federal Criminal Investigation Barrons.com
07:34AM  Fed Reportedly Opens Criminal Investigation on Opioid Makers Zacks
06:56AM  IWH UK Midco Limited -- Moody's affirms IWH's (aka Theramex) B2 ratings; changes outlook to negative Moody's
06:14AM  Pharma Companies Shares Tank As Feds Investigate Opioid Crisis Benzinga
Nov-26-19 04:15PM  Opioid Epidemic: Feds Reportedly Launch Criminal Probe Into Drugmakers Investor's Business Daily -7.93%
04:11PM  Stock Market Live Updates: Markets close at record highs Yahoo Finance
03:58PM  4 Top Stock Trades for Wednesday: DIS, PANW, BURL, TEVA InvestorPlace
01:21PM  Shares of opioid makers and distributors drop on criminal probe MarketWatch
08:36AM  Generic Drugmakers Gain as Price-Fixing Probe Nears an End Zacks
07:08AM  Shares of generic drugmakers rise on hope that legal issues are nearing an end MarketWatch
Nov-25-19 03:21PM  Teva, Others in Talks With DOJ to End Generic Drug Probe Bloomberg
12:49PM  Shares of generic drugmakers jump in morning trading MarketWatch
08:35AM  Teva, Drugmakers in Talks With U.S. to End Generics Probes Bloomberg
08:00AM  Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement Business Wire
06:06AM  [video]Teva, Generic Drugmakers Reportedly Aiming to Settle U.S. Antitrust Inquiry TheStreet.com
Nov-21-19 03:20PM  Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA Zacks
02:41PM  Biogen, Novartis named in settlement between foundation, federal prosecutors American City Business Journals
Nov-20-19 03:44PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
03:32PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
03:39AM  Corporate Bonds Are All the Rage in Emerging Markets Bloomberg
Nov-19-19 04:54PM  Teva, Bausch Could Be Next to File for Bankruptcy GuruFocus.com
01:21PM  Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes Business Wire
Nov-18-19 09:01AM  Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe Zacks
Nov-17-19 03:40PM  AbbVie's Humira on Pace to Become Biggest Seller by 2024 GuruFocus.com
Nov-15-19 03:05PM  Teva shares rise 9% MarketWatch +8.86%
Nov-14-19 01:55PM  Teva Pharmaceutical Industries Ltd -- Moody's rates Teva's new unsecured notes offering Ba2 Moody's
Nov-12-19 11:32AM  Tevas Links to Opioid Epidemic May Triple Funding Costs Bloomberg
10:47AM  Teva Vs. Amneal: JPMorgan Sees Hope For One, Decline For The Other Benzinga
09:30AM  Teva Pharmaceuticals Prospects Are Improving, Analyst Says. Hes Downbeat on a Rival. Barrons.com
08:37AM  Teva upgraded to neutral by J.P. Morgan MarketWatch
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drape EricExecutive VP Global OperationsFeb 19Sale12.518,000100,08021,494Feb 20 07:17 PM
Stark David MatthewExec. VP Chief Legal OfficerFeb 14Sale12.1417,016206,6122,974Feb 18 07:26 AM
Fridriksdottir HafrunExecutive VP, Global R&DFeb 14Sale12.1411,472139,29545,061Feb 18 07:23 AM
Drape EricExecutive VP Global OperationsFeb 14Sale12.148,14098,78529,494Feb 18 07:22 AM
Sabag MarkSee "Remarks" belowFeb 13Sale13.0372,131939,7600Feb 18 07:25 AM
Stark David MatthewExec. VP Chief Legal OfficerFeb 10Sale12.2412,538153,4712,974Feb 11 07:06 AM
O'Grady Brendan P.EVP, North America CommercialFeb 10Sale12.274,79958,88413,456Feb 11 07:02 AM
Nazzi GianfrancoEVP, Growth Markets CommercialFeb 10Sale12.244,15550,86418,464Feb 11 07:01 AM
Fridriksdottir HafrunExecutive VP, Global R&DFeb 10Sale12.275,54468,02533,330Feb 11 06:57 AM
Drape EricExecutive VP Global OperationsFeb 10Sale12.243,14438,48820,618Feb 11 06:56 AM
Dethlefs SvenEVP Global Marketing&PortfolioFeb 10Sale12.275,66969,55918,061Feb 11 06:53 AM
Daniell RichardExec. VP, European CommercialFeb 10Sale12.246,19975,8868,612Feb 11 06:52 AM
Fridriksdottir HafrunExecutive VP, Global R&DDec 31Sale9.922,45924,39622,754Jan 02 06:08 AM
Fridriksdottir HafrunExecutive VP, Global R&DDec 02Sale10.494,31045,21420,573Dec 03 06:32 AM
McClellan Michael JamesEVP, Chief Financial OfficerNov 05Sale8.832422,13815,898Nov 06 06:46 AM
Nazzi GianfrancoEVP, Growth Markets CommercialSep 18Sale7.829627,52310,678Sep 20 07:19 AM
O'Grady Brendan P.EVP, North America CommercialSep 18Sale7.834943,8692,135Sep 20 07:19 AM
McClellan Michael JamesEVP, Chief Financial OfficerSep 18Sale7.831,40611,01115,445Sep 20 07:17 AM
Griffin Deborah AChief Accounting OfficerSep 18Sale7.832,37618,6070Sep 20 07:12 AM
Daniell RichardExec. VP, European CommercialSep 18Sale7.821,1769,1971,676Sep 20 07:10 AM
Daniell RichardExec. VP, European CommercialSep 09Sale7.163332,384363Sep 11 06:58 AM
BARER SOL JDirectorJun 04Buy9.60104,5001,003,409220,442Jun 05 07:02 AM
BARER SOL JDirectorJun 03Buy8.98111,000997,013115,942Jun 03 11:21 AM
de Notaristefani CarloExecutive VP Global OperationsMay 20Sale11.4216,070183,51933,589May 21 06:38 AM
de Notaristefani CarloExecutive VP Global OperationsMay 16Sale11.766297,39718,784May 20 07:18 AM
O'Grady Brendan P.EVP, North America CommercialMar 18Sale16.631,17919,6011,388Mar 19 08:29 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 18Sale16.643205,3269,002Mar 19 08:17 AM
Daniell RichardExec. VP, European CommercialMar 18Sale16.641,29721,5880Mar 19 08:14 AM
Stark David MatthewExec. VP Chief Legal OfficerMar 18Sale16.432,35838,7422,974Mar 19 08:11 AM
McClellan Michael JamesEVP, Chief Financial OfficerMar 18Sale16.632303,82412,760Mar 19 08:08 AM
Griffin Deborah AChief Accounting OfficerMar 18Sale16.6394315,6770Mar 19 08:06 AM
Fridriksdottir HafrunExecutive VP, Global R&DMar 18Sale16.633565,91916,750Mar 19 08:04 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 18Sale16.6363210,5079,149Mar 19 08:02 AM
Stark David MatthewExec. VP Chief Legal OfficerMar 12Sale15.822,44438,6642,974Mar 14 07:44 AM
O'Grady Brendan P.EVP, North America CommercialMar 12Sale15.6773811,5681,388Mar 14 07:41 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 12Sale15.693255,0998,450Mar 14 07:36 AM
Griffin Deborah AChief Accounting OfficerMar 12Sale15.6795314,9380Mar 14 07:33 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 12Sale15.6764710,1428,602Mar 14 07:31 AM
Daniell RichardExec. VP, European CommercialMar 12Sale15.6971511,2180Mar 14 07:28 AM
O'Grady Brendan P.EVP, North America CommercialMar 04Sale16.881,16619,6861,388Mar 05 07:36 AM
McClellan Michael JamesEVP, Chief Financial OfficerMar 04Sale16.883636,12912,330Mar 05 07:28 AM
Griffin Deborah AChief Accounting OfficerMar 04Sale16.884,10769,3400Mar 05 07:23 AM
Fridriksdottir HafrunExecutive VP, Global R&DMar 04Sale16.884096,90516,094Mar 05 07:16 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 04Sale16.8860610,2318,058Mar 05 07:10 AM
Daniell RichardExec. VP, European CommercialMar 04Sale16.882,09835,4230Mar 05 07:05 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 04Sale16.885128,6457,892Mar 05 08:20 AM